Who are Ustekinumab SC's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): vunakizumab and recaticimab., BMS-986165, Ustekinumab Injection, Ustekinumab (UST).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ustekinumab-sc.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Ustekinumab SC — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ustekinumab SC (Ustekinumab SC) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-12/IL-23 inhibitor monoclonal antibody. Area: Immunology.

phase 3 IL-12/IL-23 inhibitor monoclonal antibody IL-12/IL-23 p40 subunit Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Ustekinumab SC (Ustekinumab SC) — Janssen Research & Development, LLC. Ustekinumab is a monoclonal antibody that blocks the IL-12 and IL-23 cytokines, which are key drivers of immune-mediated inflammatory responses.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ustekinumab SC TARGET	Ustekinumab SC	Janssen Research & Development, LLC	phase 3	IL-12/IL-23 inhibitor monoclonal antibody	IL-12/IL-23 p40 subunit
vunakizumab and recaticimab.	vunakizumab and recaticimab.	Xiangya Hospital of Central South University	marketed	Monoclonal antibody (anti-cytokine)	IL-12/IL-23 p40 subunit (vunakizumab); TNF-α (recaticimab)
BMS-986165	BMS-986165	Bristol-Myers Squibb	marketed	IL-12/IL-23 inhibitor	IL-12/IL-23 p40 subunit
Ustekinumab Injection	Ustekinumab Injection	National Medical Research Center for Children's Health, Russian Federation	marketed	IL-12/IL-23 inhibitor (monoclonal antibody)	IL-12/IL-23 p40 subunit
Ustekinumab (UST)	Ustekinumab (UST)	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	IL-12/IL-23 inhibitor monoclonal antibody	IL-12 p40 / IL-23 p40 subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-12/IL-23 inhibitor monoclonal antibody class)

Janssen Research & Development, LLC · 1 drug in this class
Second Affiliated Hospital, School of Medicine, Zhejiang University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ustekinumab SC — Competitive Intelligence Brief. https://druglandscape.com/ci/ustekinumab-sc. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing